Editas Medicine, Inc.

NASDAQ:EDIT

Biotechnology

Healthcare
$1.77 +2.65%

+$0.07 today

Market cap
$273.18M
Beta
2.10
P/E (TTM)
-2.4
EPS (TTM)
-$1.11
52W Low $1.66High $4.54

Volume 1.99M

Average 2.06M

EDIT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Editas Medicine, Inc.NASDAQ: EDIT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 82.9%

Gross margin was 82.9% in Q1 FY2026, up 553.8 pp from a year earlier. On a trailing-twelve-month basis it was 5.8%, up 124.1 pp year over year. Over 3 fiscal years it widened by 32.1 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
82.9%-17.1 pp QoQ
Last fiscal yearDec 2025
100.0%+616.6 pp YoY
LTMMar 2026
5.8%+124.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+553.8 pp——
1 year+616.6 pp——
3 years+32.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+616.6pp

Gross Margin vs competitors

How EDIT compares with its peers on the latest reported figures

  • EDIT's LTM Mar 2026 gross margin of 5.8% is the 4th highest of the 7 companies compared; the peer median is -35.6%.
  • Its year-over-year change of +124.1 pp is the 3rd highest of 7, against a peer median of -1.5 pp.
  • Over three fiscal years its change of +32.1 pp compares with a peer median of -6.4 pp.
EDIT Competitors Peer median
Gross Margin for EDIT and competitors
Company Period LTM level YoY 3-year change
BEAMBeam Therapeutics Inc.LTM Jun 2026100.0% +0.0 pp+495.5 pp
DTILPrecision BioSciences, Inc.LTM Mar 202697.0% -3.0 pp-8.0 pp
CRBUCaribou Biosciences, Inc.LTM Mar 202682.6% +610.6 pp-6.4 pp
EDITEditas Medicine, Inc.LTM Mar 20265.8% +124.1 pp+32.1 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-153.7% +248.0 pp-9.0 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-558.9% -202.1 pp+18649.7 pp
PRMEPrime Medicine, Inc.LTM Mar 2026-1082.7% -1182.7 pp—
BNTCBenitec Biopharma Inc.FY2025— ——
SCTXScribe Therapeutics Inc.—— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding EDIT) -35.6%-1.5 pp-6.4 pp

Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.54M19.71M78.12M32.31M40.52M
Cost of Revenue5.05M6.34M6.06M199.25M0
Gross Profit20.49M13.38M72.06M(166.93M)40.52M
Gross Margin80.2%67.9%92.2%-516.6%100.0%
Research & Development142.51M174.96M177.65M199.25M89.95M
Selling, General & Admin76.18M70.7M69.65M71.99M49.9M
Operating Expenses213.64M239.33M241.24M84.22M139.86M
Depreciation & Amortization5.05M6.34M6.06M5.81M5.28M
EBITDA(187.45M)(214.1M)(147.16M)(233.11M)(148.61M)
EBITDA Margin-733.8%-1086.1%-188.4%-721.4%-366.8%
Operating Income(193.15M)(225.95M)(169.18M)(251.15M)(99.34M)
Operating Margin-756.1%-1146.3%-216.6%-777.2%-245.2%
Interest Income607K5.52M17.57M14.06M8.31M
Interest Expense00006.17M
Other Income / Expenses644K5.52M15.96M14.06M(60.72M)
Income Before Tax(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Pre-Tax Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
Income Tax Expense00000
Net Income(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Net Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
EPS (Basic)(2.85)(3.21)(2.02)(2.88)(1.80)
EPS (Diluted)(2.85)(3.21)(2.02)(2.88)(1.80)
Weighted Avg Shares67.62M68.66M75.97M82.34M88.75M
Weighted Avg Shares (Diluted)67.62M68.66M75.97M82.34M88.75M

Editas Medicine, Inc.

NASDAQ:EDIT

Intrinsic Alpha fair value

Locked

Current Price

$1.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.